Locations:

Research

22-CNR-3405917-CQD-Hero-650×450 blood clot

December 12, 2022/Cancer/Research

Study Finds Biomarkers of Complications in Patients with Cancer Diagnosed with COVID-19

Elevated levels of vWF and FVIII associated with risk of blood clots, severe COVID-19 and death

22-CNR-3344410-CQD-Hero-650×450 Dr Gerds Momentum trial

December 9, 2022/Cancer/Research

Sustained Response Observed in MOMENTUM Trial of Patients with Myelofibrosis

Study matches momelotinib against danazol

November 3, 2022/Cancer/Research

High Rates of Breast Cancer Recurrence after Intraoperative Radiation Therapy

Research supports national guidelines for early-stage breast cancer

November 2, 2022/Cancer/Research

Questions Remain about When to Employ Immunotherapy for Resected High-Risk Melanoma

Timing of adjuvant immunotherapy unclear for maximum overall survival

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

22-CNR-3290514-CQD-Hero-650×450 lung cancer

October 27, 2022/Cancer/Research

Higher-dose Stereotactic Radiotherapy Achieves Better Control for Many Aggressive Lung Tumors

Treatment decision must be balanced against toxicity concerns

22-CNR-3290543-CQD-Hero-650×450 throat cancer

October 26, 2022/Cancer/Research

Predicting Overall Survival in HPV-Positive Oropharyngeal Squamous Cell Carcinoma

Genomic adjusted radiation dose guides treatment decision making

October 25, 2022/Cancer/Research

Biosignature Tool Predicts Individual’s Benefit from Radiation Therapy Following Breast-Conserving Therapy

Use of tool can change recommendation to add or omit radiation

22-CNR-3290544-CQD-Hero-prostate cancer 650×450

October 24, 2022/Cancer/Research

Study Reveals Gene Expression Patterns Associated With Aggressive Pathologic Features In Prostate Cancer

What is the role of molecular profiling in risk stratification?

22-CNR-3257217-CQD-Hero-Dr Geiger650x450

October 7, 2022/Cancer/Research

Cutaneous Squamous-cell Carcinoma Study Finds Complete Response to Immunotherapy in More than Half of Patients

Majority of patients achieve complete pathologic response after four-dose cemiplimab therapy

22-CNR-3235952-CQD-Hero-650×450 breast cancer

September 30, 2022/Cancer/Research

New Selective ER Modulator Shows Promising Clinical Activity in HR-positive Metastatic Breast Cancer with ESR1 Mutation After Progression

Impressive progression-free survival observed in phase 2 study

BackPage 9 of 31Next